• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    CSafe Global Appoints SVP of Technology and Innovation
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Unifying Quality Manufacturing to Drive Speed, Collaboration, and Compliance

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Baxter BioPharma Solutions

    Alcami

    Adare Pharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Emergent BioSolutions

    Alcami

    Quotient Sciences

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    CMOs & Biosimilars Mfg. in the U.S.

    Biosimilars are moving from novel opportunity to mainstream product

    CMOs & Biosimilars Mfg. in the U.S.
    CMOs & Biosimilars Mfg. in the U.S.
    CMOs & Biosimilars Mfg. in the U.S.
    Related CONTENT
    • Catalent Biologics Completes Madison Expansion
    • Pfizer's 4Q Revenues up 12%
    • Financial Report: Roche
    • CDMO Stelis Continues Expansion
    • Mogene
    Eric S. Langer and Ronald A. Rader, BioPlan Associates04.20.17
    Biosimilars are on track to become a mainstream, but niche class of the larger biopharmaceutical market, which to date has been dominated, revenue-wise, by innovative products. There is a very healthy worldwide pipeline of products in development, with over 800 biosimilars, here including about 200 biogenerics, in development and a number of already marketed biosimilars worldwide.1

    Despite the expanding markets for biosimilars, and the enthusiasm for these classes of biologics generated over the past decade, overall, the biologics industry has found the biosimilars trend to be increasingly less important. As recently as 2014, according to our “14th Annual Report and Survey of Biomanufacturing,”2 over 14% of the global industry felt biosimilars were the most important industry trend. Today, just 4% of the industry sees biosimilars as a critical trend (see Figure 1). 

    Yet, the emergence of biosimilars, especially in the U.S., where patent protection for biopharmaceuticals is essentially the strongest and longest, is going to provide the greatest opportunities in the near term.

    The patents for most modern biopharmaceuticals, e.g., recombinant proteins and antibodies, have started to expire, providing opportunities for biosimilar market entry.3 This is unlike most of the rest of the world where patent protection for marketed biopharmaceuticals, including blockbusters (>$1 billion/year sales) and others with well-established markets, have been expiring earlier than in the U.S. This has resulted in most other major highly regulated markets and many lesser-regulated international markets as well to have developed a good number of marketed biosimilars/biogenerics. For example, over 20 biosimilars are marketed in the European Union (EU). Nearly all of these are manufactured within the EU; and the EU is currently the largest market for biosimilars.

    The U.S. remains behind other major market countries in terms of biosimilar market development. Despite the U.S. market expected to be the largest market for biosimilars, much as it is for biopharmaceuticals, the U.S. is lagging in terms of number of biosimilars in the marketplace. Many of the biosimilars in development targeting the U.S. market have been hitting the brakes. In addition to patent concerns, and other issues, some biosimilars developers have been going slow due to the lack of FDA biosimilars-related guidance and regulations. For example, it took well over a decade for FDA to issue regulations concerning proper names for biosimilars. Many developers are waiting for the current U.S. market leaders, mostly the largest established (bio)pharmaceutical players, to deal with the patent-related disputes with reference product companies. Companies are also waiting for guidance concerning interchangeability.

    So far, no marketed biosimilars are being manufactured in the U.S. In fact, only one of the four FDA-approved biosimilars is marketed in the U.S., with the others delayed due to patent disputes. The one product currently in the U.S. market, Zarxio (filgrastim-sndz) from Sandoz/Novartis, is manufactured in Austria. Like Sandoz, other current European biosimilar manufacturers themselves offer CMO services and are developing multiple biosimilars for clients, for example, Boehringer Ingelheim and Rentschler. So far, no marketed biosimilar APIs or products are currently manufactured in the U.S. Nor are U.S. companies involved in the lower value international and lesser regulated biogenerics markets. However, with a large number of biosimilars in the development pipeline, most of which are targeted to the U.S. market, biosimilars in the U.S. will be taking-off and growing rapidly as new products enter the market in coming years.

    CMO manufacture of biosimilars
    Contract manufacturing organizations (CMOs) are well suited for biosimilars development, although their long-term involvement as commercial product manufacturers remains uncertain.4,5 Currently, about 30% of marketed biopharmaceuticals are commercially manufactured by CMOs, with most of this performed by just a few of the very largest biopharmaceutical CMOs. The questions today are really whether CMOs will capture greater than the current 30% market share, and how many CMOs will ultimately be involved in biosimilars production. In just 5-10 years, it is possible that half of biosimilars in the U.S. market may be manufactured by CMOs. Commercial manufacturing is an effective route for a CMO to achieve rapid growth and profitability. Some mid-sized or even small CMOs are likely to be involved in biosimilar clinical and commercial manufacturing, and as such will see the opportunity to move up and join the relatively few CMO market leaders. 

    In many respects, biosimilars are ideal products for developers to outsource development and commercial manufacturing to CMOs. Biosimilars in the U.S. today tend to be add-on small market products extending existing portfolios. Many companies may prefer to outsource biosimilar development and manufacture. Qualities, such as their smaller markets, allow biosimilars manufacture using flexible single-use-based facilities, which also makes them attractive for outsourcing to CMOs. 

    Biosimilars need to be manufactured cost-effectively to be able to compete, especially given the numbers of competitive products that will be emerging. This efficiency will generally involve adopting best available bioprocessing technologies. Biosimilars are unlikely to be manufactured by conventional bioprocessing strategies—those used by biopharma companies and CMOs over the past 20-plus years. Rather, due to the nature of the market, multiple biosimilars have to compete with each other, as well as their reference product, biobetters and other products targeting the same indications. So biosimilar manufacturing needs to provide a cost-based competitive advantage that translates to lower prices. While analysts are now beginning to cite 50% discounts (vs. reference product) in the U.S. vs. the prior consensus of 25-30%, we believe there will be increasingly fierce competition in the U.S., with potentially even higher discounts likely for at least some products. Profit margins may eventually erode and begin to resemble generic drugs rather than biopharmaceuticals.
     
    Use of new, innovative, efficient bioprocessing technologies for biosimilars will be a necessity. Nearly all biosimilar development and manufacturing today involves use of state-of-the-art technology, just to be cost-competitive. This includes a disproportionate percentage of products destined to be manufactured using single-use systems, optimized bioprocesses, culture media, etc. These are activities where CMOs have an advantage, and because they work on many different systems and platforms, can often be better, quicker, and cheaper for doing biosimilar development and manufacture vs. developers doing it themselves. Biosimilars have already proven themselves as not being exceptionally hard or expensive to bring to market, which also supports use of CMOs. CMOs have more relevant experience compared to developers, including having experience with many more products, and most already are involved with biosimilars development. In addition, CMOs tend to be more flexible and adaptable. These characteristics provide CMOs advantages for biosimilars products compared to other biologics classes. And this is showing up in CMOs’ pipelines and on their bottom lines. Already, anecdotally, CMOs are seeing significant development business for biosimilars, and they have been reporting as much as 15% of revenue coming from biosimilars. And for the many CMOs doing development, and early-stage bioprocessing for biosimilars, we can expect to see continuation of their work as products move into commercial manufacturing scales.

    Biosimilars manufacture in the U.S.
    In the near term, most biosimilars entering the U.S. market will have been developed, approved and marketed first and generally manufactured in other major markets, primarily in Europe. But with the U.S. the largest market for biosimilars and being dominant in biopharmaceutical manufacturing, significant manufacturing will be done in the U.S., if only for the domestic market. So, biosimilars manufacturing will be increasing rapidly in the U.S., but starting at current near zero baseline. Reflecting the importance of the U.S. market, the Biosimilars/Biobetters Pipeline Database currently reports 235 U.S.-based companies significantly involved as developers, manufacturers or marketers in biosimilars vs. 177 in Europe, 57 in India, and 49 in China, with most of the non-U.S./non-EU companies primarily involved with biogenerics, which most of these developers hope to sooner or later bring to Western markets, particularly the U.S.1 (see Figure 2).

    Competition for CMOs from mainstream biopharma manufacturers
    Titers and yields have significantly improved since the older legacy facilities manufacturing blockbuster mAbs came online. Average titers have increased from a few tenths of a gram several decades ago to 3.5 g/L or greater.2 Besides reducing manufacturing costs, this has resulted in many of the very largest biopharmaceutical companies increasingly to offer CMO manufacturing services by providing access to their excess capacity. Thus, in addition to dedicated CMOs, many Big (Bio)Pharma companies are also becoming CMOs. Many of these largest legacy stainless steel facilities are still in the U.S. So, CMO involvement with biosimilar manufacture in the U.S. could well involve a mix of mainstream CMOs, most using smaller single-use systems for manufacturing, and very large, legacy, stainless steel-based, commercial manufacturing facilities, with biosimilars manufacture filling in gaps in these facilities’ manufacturing schedules. 

    There will be a variety of approaches taken for manufacturing biosimilars in the U.S. For example, some new entrants to biopharmaceutical manufacturing may opt to develop their own facilities in-house, often as a bridge to getting their products into the market, with successful products expected to be licensed by major marketers, and from there manufacturing either assumed by that company or transferred to a CMO. For example, most biopharmaceutical CMOs have in recent years developed the capabilities to offer larger-scale, e.g., 2,000 L bioreactor manufacturing services. Some companies, such as Oncobiologics, have built their own manufacturing facilities, often as an intermediate launch facility to get through late-stage trials and initial product launch. But many developers will likely use CMOs for product manufacture, particularly where they developed single-use-based bioprocesses. A number of biosimilars will likely have their full development and manufacture outsourced. This simply will be faster and often cheaper than a company doing development and production in-house.

    Product manufacture in the U.S. has always been a good selling point. FDA biologics approvals are viewed as a “gold standard.” Many view U.S.-manufactured products as generally being high-tech, etc. So biosimilar manufacture in the U.S. may provide some marketing advantages, although without any clinical data, these cannot be promoted or advertised as such. Manufacturing location may be one of the few aspects that marketers can point to as differentiating their biosimilars. This includes citing U.S. manufacture, while other biosimilars will be imported in to the U.S. Whether pricing based on location of manufacture becomes a competitive factor will remain to be seen.

    Perhaps we may see biosimilars initially manufactured overseas ultimately being transferred and manufactured in U.S. by a CMO. If a biosimilars developer does not expect to have sufficient market share to warrant building their own dedicated US manufacturing facilities, they may also rely on a CMO. Also, just as how some U.S.-developed and manufactured innovative biopharmaceuticals have second-source CMO backup manufacturing facilities in Europe or other regions, some foreign biosimilar developer manufacturers may find it prudent to also manufacture in the U.S., with CMOs likely being a cost-effective option. 

    Biosimilars will definitely continue to be a major growth area for U.S. biopharmaceutical CMOs, and U.S. bioprocessing facilities’ involvement in biosimilars manufacturing and their manufacturing capacities will continue to show expansion to meet the needs of this growing niche.6 

    References
    1. Rader, R.A., “Biosimilars/Biobetters Pipeline Database,” at www.biosimilarspipeline.com.
    2. 14th Annual Report and Survey of Biopharmaceutical Manufacturing, April 2017, www.bioplanassociates.com.
    3. Rader, R.A., BIOPHARMA:  Biopharmaceutical Products in the U.S. and European Markets, at www.biopharma.com.
    4. Rader, R.A.,, Langer, E.S., “Biosimilars Outsourcing and Capacity:  CMOs to play important but uncertain role in biosimilars manufacturing,” Contract Pharma, May 2016.
    5. Rader. R.A., Langer, E.S., “Biosimilars Improving Efficiency and Cost for All Biologics,” Contract Pharma, April 2015, p. 28-30.
    6. Top 1000 Global Biopharmaceutical Facilities Index, at www.top1000bio.com.

    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com

    Ronald A. Rader
    Bioplan Associates

    Ronald A. Rader, Senior Director, Technical Research, 25+ years experience as a biotechnology, pharmaceutical and chemical information specialist and publisher. Editor/Publisher of the Antiviral Agents Bulletin periodical, the Federal Bio-Technology Transfer Directory, Biopharmaceutical Products in the U.S. Market. Mr. Rader has been Manager of Information Services, Porton International plc, Gillette Medical Evaluation Labs., MITRE Corp.; Technical Resources Inc.; and Bio-Conversion Labs. +1 301-921-5979 info@bioplanassociates.com 
    Related Searches
    • single-use systems
    • contract manufacturing organizations
    • Filling
    • Biopharma
    Suggested For You
    Catalent Biologics Completes Madison Expansion Catalent Biologics Completes Madison Expansion
    Pfizer Pfizer's 4Q Revenues up 12%
    Financial Report: Roche Financial Report: Roche
    CDMO Stelis Continues Expansion CDMO Stelis Continues Expansion
    Mogene Mogene
    Stelis BioSource Continues Facility Investment Stelis BioSource Continues Facility Investment
    Financial Report: Pfizer Financial Report: Pfizer
    Pharmaceutical Excipients Market Poised for Growth Pharmaceutical Excipients Market Poised for Growth
    Financial Report: Biogen Financial Report: Biogen
    Vetio Animal Health Vetio Animal Health
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    Indian Generic Firms  Expand Biosimilar Portfolios Indian Generic Firms Expand Biosimilar Portfolios
    The FDA and Metrics The FDA and Metrics
    Biosimilars Update Biosimilars Update

    Related Columns

    • Biosimilars
      The Bioprocessing Trek

      The Bioprocessing Trek

      Biosimilars are the next speed-bump for CMOs
      Emil W. Ciurczak, DoraMaxx Consulting 09.16.19

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17


    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16

    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16


    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15

    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15


    • Biosimilars | Fill/Finish | QA/QC

      CMOs Are Willing to Pay for More Innovation

      Downstream improvements top the list
      Eric S. Langer, BioPlan Associates 09.11.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15

    • Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      Biosimilars and Their Future in Medicine

      The first step is understanding what biosimilars actually are
      Ben Locwin, Healthcare Science Advisors 06.02.15


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    • APIs | Biosimilars | Process Development | Supply Chain

      Biosimilars Improving Efficiency, Cost for All Biologics

      ...
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15

    Trending
    • Franco Negron Named CEO Of ApiJect Systems America
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    Breaking News
    • Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    • KemPharm Receives $10M Milestone for FDA Approval of Azstarys
    • Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax
    • Syneos, Medable Partner for New Decentralized Capabilities
    • CSafe Global Appoints SVP of Technology and Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ashland Supports the Nature Conservancy Forest Restoration Effort to Help Plant a Billion Trees
    Martin Bauer Announces Installation of Agile Filling System at Bethlehem, PA Facility
    PepsiCo and Ingredion Begin Pilot Partnership with Soil and Water Outcomes Fund
    Coatings World

    Latest Breaking News From Coatings World

    AkzoNobel Shareholders Approve Final Dividend at Annual General Meeting
    Sustainable Plastics Will Make Up More Than 15% of Production by 2030
    Axalta Coating Systems Announces $625 Million Increase to Share Repurchase Program Authorization
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Receives FDA Clearance for Multiple Products
    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    TEAM Technologies Acquires ViruDefense
    Contract Pharma

    Latest Breaking News From Contract Pharma

    RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt
    Bora Pharmaceuticals Completes Health Canada Inspection
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Knoll Printing & Packaging Commits to a Healthy Ocean and Planet
    New Sustainable Jar from APC Packaging
    Qosmedix Launches Corporate Social Responsibility Initiative
    Happi

    Latest Breaking News From Happi

    Multi-Purpose Sustainable 'Just Add Water' Household Cleaner Expands Cleaning Products
    Kao Launches Oribe in Japan
    Love Beauty and Planet Shares Sustainability Initiatives With Refillable Hair Care at Target
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    SE-DA Invests in Kornit Presto S
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson upgrades SurePress demo facility
    Xeikon helps converters navigate toner and inkjet
    Mactac introduces Simply Sustainable initiative
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Savaré Strengthens Technical Support for the Americas
    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversions Launches Wipes Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Orthofix's 3D-Printed FORZA Titanium TLIF Spacer System
    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv, Ameta International Announce US, Canadian Distribution Partnership
    Adesis Achieves ISO 9001:2015 Certification
    Louis Widmer SA Complies with EU Anti-Counterfeiting Directive with Zebra Technologies’ Solution

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login